Another myeloid cell-based approach involves inhibiting certain cytokines, chemokines, or their receptors, including CXCR2 (C-X-C motif chemokine receptor 2) and targeting checkpoints, thereby increasing T-cell filtration into the tumor and effectively killing tumor cells as a result [47]. The gene discussed is CXCR2; the disease is neoplasm.